IXICO PLC told investors it has added around £1.5 million of contracted revenue after extending an agreement tied to a global Phase 2 clinical trial in Huntington’s Disease.
The AIM-listed neuroscience imaging and biomarker analytics group said the extension follows continued progress in the study with one of the world’s leading international pharmaceutical companies, although it did not name the customer.
The additional revenue is expected to be delivered over the next three years.
Chief executive Bram Goorden said: "This is another example of how IXICO's compelling IXI™ technology platform and neurological disease expertise consistently deliver gold standard outcomes for biopharma customers as they advance drug development in such a devastating neurological disease," Goorden said.
Around a week ago, IXICO announced the appointment of Tanya Voloshen as its chief commercial officer, in a newly created role, as the firm seeks to accelerate business development activity and broaden its US footprint.
** Correction: content updated after Ixico reissued the RNS